









Markets
/
Stocks
/
nasdaq-hae
/

Haemonetics Corp

HAE

50.600USD

-0.550-1.08%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.44BMarket Cap

14.92P/E TTM



Haemonetics Corp

50.600

-0.550-1.08%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

60 / 207

Overall Ranking

140 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

80.300

Target Price

+56.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 16.44% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 45.30.

Undervalued

The company’s latest PE is 15.40, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 57.31M shares, decreasing 6.82% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.94M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.27.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.20, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 321.39M, representing a year-over-year decrease of 4.40%, while its net profit experienced a year-over-year decrease of 11.32%.

Score

Industry at a Glance

Previous score

7.20

Change



Financials

8.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.53

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.93

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.98

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.40, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is 15.57, which is 57.87% below the recent high of 24.58 and -23.18% above the recent low of 19.18.

Score

Industry at a Glance

Previous score

3.40

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 60/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.18, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Haemonetics Corp is 78.00, with a high of 108.00 and a low of 58.00.

Score

Industry at a Glance

Previous score

8.18

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

80.300

Target Price

+56.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Haemonetics Corp

HAE

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.46, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 55.38 and the support level at 48.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.458

Neutral

RSI(14)

30.555

Neutral

STOCH(KDJ)(9,3,3)

23.027

Neutral

ATR(14)

1.304

Low Volatility

CCI(14)

-98.219

Neutral

Williams %R

78.212

Sell

TRIX(12,20)

-0.640

Sell

StochRSI(14)

79.932

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

50.814

Sell

MA10

52.176

Sell

MA20

53.389

Sell

MA50

61.603

Sell

MA100

65.805

Sell

MA200

67.475

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 118.95%, representing a quarter-over-quarter decrease of 1.23%. The largest institutional shareholder is The Vanguard, holding a total of 4.94M shares, representing 10.26% of shares outstanding, with 0.31% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.67M

+0.55%

The Vanguard Group, Inc.

Star Investors

5.09M

-1.56%

Neuberger Berman, LLC

4.35M

-1.61%

Wellington Management Company, LLP

2.62M

-33.38%

State Street Global Advisors (US)

1.92M

-1.49%

River Road Asset Management, LLC

1.40M

+295.76%

T. Rowe Price Investment Management, Inc.

2.20M

-14.03%

Royce Investment Partners

Star Investors

1.16M

+0.70%

Geode Capital Management, L.L.C.

1.22M

+3.41%

Capital Research Global Investors

1.58M

-62.79%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.56, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.